Britannia Life Sciences Inc. Provides Update on Cease Trade Order
Toronto, Ontario and London, United Kingdom--(Newsfile Corp. - August 12, 2024) - Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020)...
Month: August 2024
Masimo W1® Medical Watch Receives FDA 510(k) Clearance for Connectivity to the Masimo SafetyNet® Telemonitoring System
Secure Bluetooth® Connectivity Allows Continuous, Accurate Wrist-based Measurements to be Seamlessly Relayed to Caregivers via the Masimo Secure Health Data...
Orphan Drugs and Rare Diseases Conference (Boston, MA, United States – October 17-18, 2024) – Navigating Orphan Drugs & Rare Diseases from Regulation to Detection & Precision Treatments – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Orphan Drugs and Rare Diseases Conference" has been added to ResearchAndMarkets.com's offering. The 2 day Orphan Drugs and...
Bemax Inc. Completes Acquisition of Kona Gold, LLC
Strategic Move Solidifies Bemax's Position in the Consumer-Packaged Goods MarketDallas, Georgia--(Newsfile Corp. - August 12, 2024) - Bemax Inc. (OTC...
Monogram Technologies Secures Initial Strategic Clinical Trial Collaboration
Clinical Trial Collaboration Follows 510(k) Submission and Passing of FDA Administrative Review; Preludes Planned International Launch for the mBȏs TKA...
R1 RCM Named Top Performing Revenue Cycle Management Outsourcing Provider by 2024 Black Book Health Systems Client Survey
Managed services customers validated highest client satisfaction ratings on R1 RCM, a major player in the medical financial services industry...
CBD Life Sciences, Inc. (CBDL) Welcomes Major Political Endorsement for Cannabis Legalization
SCOTTSDALE, AZ / ACCESSWIRE / August 12, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), including its wholly owned subsidiary,...
MIRA Pharmaceuticals Unveils Ketamir-2’s Principal Metabolite: Nor-Ketamir – a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
This breakthrough in bioavailability and formulation showcases the potential for advanced, at home neurological treatments.MIAMI, FL / ACCESSWIRE / August...
Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024
SAN DIEGO, CA / ACCESSWIRE / August 12, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare...
Theralase(R) Release’s 2Q2024 Financial Statements
TORONTO, ON / ACCESSWIRE / August 12, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
Interactive Strength Inc. (Nasdaq: TRNR) Wins Appeal for Continued Nasdaq Listing
AUSTIN, TX / ACCESSWIRE / August 12, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or "the Company"), maker of innovative...
Parexel’s Near-Term Greenhouse Gas Reduction Targets Validated by Science Based Target Initiative (SBTi)
DURHAM, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the...
ObservSMART Adds Clinical Expert, Susan Branagan, to Their Team
PHILADELPHIA, Aug. 12, 2024 /PRNewswire/ -- InvisALERT Solutions – ObservSMART is pleased to announce the addition of Susan "Susie" Branagan,...
Vrtly Introduces Vrtly Ad Manager: Revolutionizing Digital Content Distribution for Brands
SAN RAMON, Calif., Aug. 10, 2024 /PRNewswire/ -- Vrtly, the leading Point-of-Care (POC) ad platform for Medical Aesthetics, is thrilled to...
MAPS Statement on FDA Complete Response Letter for MDMA-Assisted Therapy for PTSD New Drug Application
MAPS remains confident in its goal of making access to MDMA-assisted therapy for PTSD safe and legal SAN JOSE, Calif.,...
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology...
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1...
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to...
Acorn Credentialing to Showcase Cutting-Edge Credentialing Solution at NACDS Event
DELRAY BEACH, Fla., Aug. 9, 2024 /PRNewswire/ -- Acorn Credentialing, a leading provider of automated and intelligent credentialing solutions, is...
FSD Pharma Announces Share Consolidation and Name Change
Toronto, Ontario--(Newsfile Corp. - August 9, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9) ("FSD Pharma" or...